Table 1.
Baseline characteristics
| Characteristics | HAIC+L+P Group | TACE+L+P Group | X2 Value | P Value |
|---|---|---|---|---|
| Gender | - | 0.04 | ||
| Male | 27 | 58 | ||
| Female | 7 | 3 | ||
| Age | 4.04 | 0.04 | ||
| < 50 | 16 | 15 | ||
| ≥ 50 | 18 | 46 | ||
| HBsAg | - | 0.70 | ||
| Positive | 31 | 57 | ||
| Negative | 3 | 4 | ||
| Liver cirrhosis | 0.325 | 0.568 | ||
| Yes | 21 | 34 | ||
| No | 13 | 27 | ||
| ECOG | 1.83 | 0.18 | ||
| 0 | 10 | 28 | ||
| 1 | 24 | 33 | ||
| Child Pugh | 1.08 | 0.30 | ||
| A | 25 | 37 | ||
| B | 9 | 24 | ||
| Maximum tumor diameter | - | 0.65 | ||
| < 5 cm | 3 | 8 | ||
| 5-10 cm | 12 | 25 | ||
| > 10 cm | 19 | 28 | ||
| Tumor capsule | 5.81e-31 | 1.00 | ||
| Complete | 15 | 27 | ||
| Incomplete | 19 | 34 | ||
| AFP | 5.19 | 0.02 | ||
| < 400 ng/ml | 11 | 36 | ||
| ≥ 400 ng/ml | 23 | 25 | ||
| Number of tumors | 3.55e10-31 | 1.00 | ||
| ≤ 3 | 13 | 24 | ||
| > 3 | 21 | 37 | ||
| PVTT | 1.62 | 0.45 | ||
| Vp2 | 10 | 26 | ||
| Vp3 | 13 | 19 | ||
| Vp4 | 11 | 16 | ||
| Hepatic vein invasion | 0.26 | 0.61 | ||
| Yes | 5 | 13 | ||
| No | 29 | 48 | ||
| Extrahepatic metastases | 0.50 | 0.48 | ||
| Yes | 9 | 11 | ||
| No | 25 | 50 | ||
| Lymph node metastases | 0.49 | 0.49 | ||
| Yes | 6 | 16 | ||
| No | 28 | 45 |
ECOG: Eastern Cooperative Oncology Group; PVTT: portal vein tumor thrombus; Vp2: the presence of a PVTT in the second-order branches of the portal vein; Vp3: the presence of a PVTT in the first-order branches of the portal vein; Vp4: the presence of a PVTT in the main trunk of the portal vein or a contralateral portal vein branch or both.